Last Updated: July 14, 2026

Investigational Drug Information for AMX0035


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for AMX0035?

AMX0035 is an investigational drug.

There have been 10 clinical trials for AMX0035. The most recent clinical trial was a Phase 2 trial, which was initiated on November 8th 2024.

The most common disease conditions in clinical trials are Amyotrophic Lateral Sclerosis, Motor Neuron Disease, and Sclerosis. The leading clinical trial sponsors are Amylyx Pharmaceuticals Inc., Massachusetts General Hospital Neurology Clinical Research Institute, and ALS Finding a Cure.

There are eight US patents protecting this investigational drug and fourteen international patents.

Recent Clinical Trials for AMX0035
TitleSponsorPhase
A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALSUniversité de MontréalPHASE2
A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALSOliver BlanchardPHASE2
AMX0035 and Progressive Supranuclear PalsyAmylyx Pharmaceuticals Inc.Phase 3

See all AMX0035 clinical trials

Clinical Trial Summary for AMX0035

Top disease conditions for AMX0035
Top clinical trial sponsors for AMX0035

See all AMX0035 clinical trials

US Patents for AMX0035

Glossary
Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AMX0035 ⤷  Start Trial Method of treating amyotrophic lateral sclerosis with pridopidine Prilenia Neurotherapeutics Ltd ⤷  Start Trial
AMX0035 ⤷  Start Trial Compositions of bile acids and phenylbutyrate compounds Amylyx Pharmaceuticals Inc ⤷  Start Trial
AMX0035 ⤷  Start Trial Compositions of bile acids and phenylbutyrate compounds Amylyx Pharmaceuticals Inc ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links